Skip to main content
Top
Published in: BMC Pediatrics 1/2021

Open Access 01-12-2021 | Secondary Hemophagocytic Lymphohistiocytosis | Case report

Wolman’s disease presenting with secondary hemophagocytic lymphohistiocytosis: a case report from Saudi Arabia and literature review

Authors: Fahad Alabbas, Ghaleb Elyamany, Talal Alanzi, Tahani Bin Ali, Fatma Albatniji, Huda Alfaraidi

Published in: BMC Pediatrics | Issue 1/2021

Login to get access

Abstract

Background

Hemophagocytic lymphohistiocytosis (HLH) is a rare and potentially fatal syndrome that is characterized by strong activation of the immune system from hyperinflammatory cytokines. Symptoms of HLH patients include fever, hepatosplenomegaly, cytopenia, and hyperferritinemia. Inherited HLH is classified as primary, whereas secondary HLH (sHLH) occurs when acquired from non-inherited reasons that include severe infection, immune deficiency syndrome, autoimmune disorder, neoplasm, and metabolic disorder. Wolman’s disease (WD) is a rare and fatal infantile metabolic disorder caused by lysosomal acid lipase deficiency, that exhibits similar clinical signs and symptoms as HLH. This paper reports the case of an infant diagnosed with WD and who presented with sHLH.

Case presentation

A 4-month-old infant presenting with hepatosplenomegaly, failure to thrive, and other abnormalities. WD diagnosis was confirmed by the presence of the LIPA gene homozygous deletion c.(428 + 1_967-1)_(*1_?)del. The infant also met the HLH-2004 diagnostic criteria.

Conclusions

Metabolic disorder such as WD should be investigated in infants fulfilling the HLH criteria to diagnose the underlying condition. More studies are needed to understand the link between WD and sHLH and to identify appropriate therapies.
Literature
1.
go back to reference Janka GE, Lehmberg K. Hemophagocytic lymphohistiocytosis: pathogenesis and treatment. Hematology. 2013;2013(1):605–11.CrossRef Janka GE, Lehmberg K. Hemophagocytic lymphohistiocytosis: pathogenesis and treatment. Hematology. 2013;2013(1):605–11.CrossRef
2.
go back to reference Jordan MB, Allen CE, Greenberg J, Henry M, Hermiston ML, Kumar A, et al. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019;66(11):e27929.CrossRef Jordan MB, Allen CE, Greenberg J, Henry M, Hermiston ML, Kumar A, et al. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019;66(11):e27929.CrossRef
3.
go back to reference Henter JI, Samuelsson-Horne A, Arico M, Egeler RM, Elinder G, Filipovich AH, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367–73.CrossRef Henter JI, Samuelsson-Horne A, Arico M, Egeler RM, Elinder G, Filipovich AH, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367–73.CrossRef
4.
go back to reference Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatric blood cancer. 2007;48(2):124–31.CrossRef Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatric blood cancer. 2007;48(2):124–31.CrossRef
5.
go back to reference Marsh RA, Haddad E. How I treat primary haemophagocytic lymphohistiocytosis. Br J Haematol. 2018;182(2):185–99.CrossRef Marsh RA, Haddad E. How I treat primary haemophagocytic lymphohistiocytosis. Br J Haematol. 2018;182(2):185–99.CrossRef
6.
go back to reference Pericleous M, Kelly C, Wang T, Livingstone C, Ala A. Wolman’s disease and cholesteryl ester storage disorder: the phenotypic spectrum of lysosomal acid lipase deficiency. The lancet Gastroenterology hepatology. 2017;2(9):670–9.CrossRef Pericleous M, Kelly C, Wang T, Livingstone C, Ala A. Wolman’s disease and cholesteryl ester storage disorder: the phenotypic spectrum of lysosomal acid lipase deficiency. The lancet Gastroenterology hepatology. 2017;2(9):670–9.CrossRef
7.
go back to reference Erwin AL. The role of sebelipase alfa in the treatment of lysosomal acid lipase deficiency. Therapeutic advances in gastroenterology. 2017;10(7):553–62.CrossRef Erwin AL. The role of sebelipase alfa in the treatment of lysosomal acid lipase deficiency. Therapeutic advances in gastroenterology. 2017;10(7):553–62.CrossRef
8.
go back to reference Althonaian N, Alsultan A, Morava E, Alfadhel M. Secondary hemophagocytic syndrome associated with COG6 gene defect: report and review. JIMD Reports. 2018;42:105–11.CrossRef Althonaian N, Alsultan A, Morava E, Alfadhel M. Secondary hemophagocytic syndrome associated with COG6 gene defect: report and review. JIMD Reports. 2018;42:105–11.CrossRef
9.
go back to reference Lee TM, Welsh M, Benhamed S, Chung WK. Intragenic deletion as a novel type of mutation in Wolman disease. Mol Genet Metab. 2011;104(4):703–5.CrossRef Lee TM, Welsh M, Benhamed S, Chung WK. Intragenic deletion as a novel type of mutation in Wolman disease. Mol Genet Metab. 2011;104(4):703–5.CrossRef
10.
go back to reference Ghosh A, Schlecht H, Heptinstall LE, Bassett JK, Cartwright E, Bhaskar SS, et al. Diagnosing childhood-onset inborn errors of metabolism by next-generation sequencing. Arch Dis Child. 2017;102(11):1019–29.CrossRef Ghosh A, Schlecht H, Heptinstall LE, Bassett JK, Cartwright E, Bhaskar SS, et al. Diagnosing childhood-onset inborn errors of metabolism by next-generation sequencing. Arch Dis Child. 2017;102(11):1019–29.CrossRef
11.
go back to reference Al Essa M, Nounou R, Sakati N, Le Quesne G, Joshi S, Archibald A, et al. Wolman’s disease: The King Faisal Specialist Hospital and Research Centre experience. Ann Saudi Med. 1998;18(2):120–4.CrossRef Al Essa M, Nounou R, Sakati N, Le Quesne G, Joshi S, Archibald A, et al. Wolman’s disease: The King Faisal Specialist Hospital and Research Centre experience. Ann Saudi Med. 1998;18(2):120–4.CrossRef
12.
go back to reference Perry R, Kecha O, Paquette J, Huot C, Van Vliet G, Deal C. Primary adrenal insufficiency in children: twenty years experience at the Sainte-Justine Hospital, Montreal. The Journal of Clinical Endocrinology Metabolism. 2005;90(6):3243–50.CrossRef Perry R, Kecha O, Paquette J, Huot C, Van Vliet G, Deal C. Primary adrenal insufficiency in children: twenty years experience at the Sainte-Justine Hospital, Montreal. The Journal of Clinical Endocrinology Metabolism. 2005;90(6):3243–50.CrossRef
13.
go back to reference Rabah F, Al-Hashmi N, Beshlawi I. Wolman’s disease with secondary hemophagocytic lymphohistiocytosis. Pediatric hematology oncology. 2014;31(6):576–8.CrossRef Rabah F, Al-Hashmi N, Beshlawi I. Wolman’s disease with secondary hemophagocytic lymphohistiocytosis. Pediatric hematology oncology. 2014;31(6):576–8.CrossRef
14.
go back to reference Taurisano R, Maiorana A, De Benedetti F, Dionisi-Vici C, Boldrini R, Deodato F. Wolman disease associated with hemophagocytic lymphohistiocytosis: attempts for an explanation. Eur J Pediatr. 2014;173(10):1391–4.CrossRef Taurisano R, Maiorana A, De Benedetti F, Dionisi-Vici C, Boldrini R, Deodato F. Wolman disease associated with hemophagocytic lymphohistiocytosis: attempts for an explanation. Eur J Pediatr. 2014;173(10):1391–4.CrossRef
15.
go back to reference Elsayed S, Elsobky E, Tantawy A, Ragab E, Gil M, Lambert N, et al. Wolman disease in patients with familial hemophagocytic lymphohistiocytosis (FHL) negative mutations. Egyptian Journal of Medical Human Genetics. 2016;17(3):277–80.CrossRef Elsayed S, Elsobky E, Tantawy A, Ragab E, Gil M, Lambert N, et al. Wolman disease in patients with familial hemophagocytic lymphohistiocytosis (FHL) negative mutations. Egyptian Journal of Medical Human Genetics. 2016;17(3):277–80.CrossRef
16.
go back to reference Yavaş AK, Orhaner B, Genç P, Kılıç N, Erdoğan H, Özdemir Ö, et al. Secondary hemophagocytic lymphohistiocytosis in an infant with Wolman disease. Turkish Journal of Hematology. 2017;34(3):264. Yavaş AK, Orhaner B, Genç P, Kılıç N, Erdoğan H, Özdemir Ö, et al. Secondary hemophagocytic lymphohistiocytosis in an infant with Wolman disease. Turkish Journal of Hematology. 2017;34(3):264.
17.
go back to reference Tinsa F, Ben Romdhane M, Boudabous H, Bel Hadj I, Brini I, Tebib N, et al. A novel mutation c. 153 C > A in a Tunisian girl with Wolman disease and unusual presentation: hemophagocytic lymphohistiocytosis. Journal of Pediatric Hematology/Oncology. 2019;41(3):e193-6.CrossRef Tinsa F, Ben Romdhane M, Boudabous H, Bel Hadj I, Brini I, Tebib N, et al. A novel mutation c. 153 C > A in a Tunisian girl with Wolman disease and unusual presentation: hemophagocytic lymphohistiocytosis. Journal of Pediatric Hematology/Oncology. 2019;41(3):e193-6.CrossRef
18.
go back to reference Bergsten E, Horne A, Aricó M, Astigarraga I, Egeler RM, Filipovich AH, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017;130(25):2728–38.CrossRef Bergsten E, Horne A, Aricó M, Astigarraga I, Egeler RM, Filipovich AH, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017;130(25):2728–38.CrossRef
19.
go back to reference Yanagisawa R, Nakazawa Y, Matsuda K, Yasumi T, Kanegane H, Ohga S, et al. Outcomes in children with hemophagocytic lymphohistiocytosis treated using HLH-2004 protocol in Japan. Int J Hematol. 2019;109(2):206–13.CrossRef Yanagisawa R, Nakazawa Y, Matsuda K, Yasumi T, Kanegane H, Ohga S, et al. Outcomes in children with hemophagocytic lymphohistiocytosis treated using HLH-2004 protocol in Japan. Int J Hematol. 2019;109(2):206–13.CrossRef
20.
go back to reference Vallurupalli M, Berliner N. Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. Blood. 2019;134(21):1783–6.CrossRef Vallurupalli M, Berliner N. Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. Blood. 2019;134(21):1783–6.CrossRef
Metadata
Title
Wolman’s disease presenting with secondary hemophagocytic lymphohistiocytosis: a case report from Saudi Arabia and literature review
Authors
Fahad Alabbas
Ghaleb Elyamany
Talal Alanzi
Tahani Bin Ali
Fatma Albatniji
Huda Alfaraidi
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Pediatrics / Issue 1/2021
Electronic ISSN: 1471-2431
DOI
https://doi.org/10.1186/s12887-021-02541-2

Other articles of this Issue 1/2021

BMC Pediatrics 1/2021 Go to the issue